In obese patients or patients with type II diabetes, circulating IGFBP-2 levels are low, while the overexpression of IGFBP-2 protects against the disease by inhibiting adipogenesis and modulating insulin sensitivity [54]. Here, INS is linked to type 2 diabetes mellitus.